top stories

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

14 hours ago
People
Pharma

No­var­tis jumps in­to Covid-19 vac­cine hunt, as Big Phar­ma and big biotech com­mit to bil­lions of dos­es

13 hours ago
Coronavirus

Covid-19 roundup: FDA's Stephen Hahn per­son­al­ly helped a doc­tor set up hy­drox­y­chloro­quine tri­al — re­port

16 hours ago
Coronavirus

As­traZeneca trum­pets the good da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ...

6 hours ago
R&D

Latest

Most read

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Yesterday
Bioregnum
R&D

Pro­tal­ix files BLA to com­pete with Sanofi Gen­zyme; Rally­bio col­lects an­oth­er Alex­ion alum

12 hours ago
Protocols

In for the long vac­cine game, Mer­ck buys in­to patch de­liv­ery tech with pan­dem­ic po­ten­tial

13 hours ago
R&D

De­nali un­veils new way of cross­ing blood brain bar­ri­er as the big neu­ro­science bet en­ters its clin­i­cal years

15 hours ago
R&D

FDA ex­plains im­pact of Covid-19 on ap­pli­ca­tions, for­mal meet­ings

17 hours ago
Regulatory
Coronavirus

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

20 hours ago
R&D
Coronavirus
see latest stream
People

Drug de­vel­op­er, Big Phar­ma com­mer­cial ex­ec, now an up­start biotech chief — Fab­rice Chouraqui is ready to try ...

23 hours ago

Stymied by the pan­dem­ic, Im­munomedic­s' new CEO bows out, tak­ing a mil­lion bucks plus perks as he heads out the ...

Yesterday

Ex-biotech chief pleads guilty in col­lege ad­mis­sions scan­dal, faces a 10-month prison stretch in plea deal

2 days ago
Startups

For a post-Soliris world, At­las-backed Q32 Bio out­lines $46M next-gen com­ple­ment play

Yesterday

Daphne Koller’s AI start­up gets $143M in new cash from a16z, oth­ers

2 days ago

Be­zos, Paul Allen funds, a16z put up $100M to build an Il­lu­mi­na of hu­man pro­teins

Last week
Deals

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Yesterday

In lat­est can­cer deal, Bris­tol My­ers Squib­b's new BD chief bets $65M in search for more tar­gets like PARP

Yesterday

PhII Alzheimer's da­ta loom­ing, Sh­iono­gi spend­ing up to $500M on a buy­out in­volv­ing one of the tough­est bets in ...

2 days ago
IPOs

As biotech IPOs siz­zle on vir­tu­al Wall Street, 3 new play­ers roll the dice on meg­a­money gam­bles top­ping $325M

2 days ago

A lit­tle-known biotech run­ning low on cash looks to get its own $100M IPO from pan­dem­ic mar­ket

Last week

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

Last week

Premium storiesSee all

Macro­Gen­ics CEO Scott Koenig gets the pre-AS­CO par­ty start­ed with some en­cour­ag­ing pipeline tid­bits — leav­ing lots ...

3 weeks ago
Bioregnum
R&D

Deal­mak­ing spiked to record lev­els in April as Covid-19 trig­gered a fever of part­ner­ing. But what hap­pens to ...

4 weeks ago
Deals

Full steam ahead, Pfiz­er goes bar­gain hunt­ing in an age of coro­n­avirus — with a spe­cial fo­cus on can­cer and rare ...

5 weeks ago
Bioregnum
R&D

A slice of half-baked remde­sivir da­ta takes a dark turn — but we're still wait­ing for a de­fin­i­tive study

Last month
Bioregnum
R&D

Don't missSee all

Covid-19 roundup: Buoyed by soar­ing shares, No­vavax inks a $167M deal to buy Covid-19 vac­cine-mak­ing fa­cil­i­ty; France ...

Yesterday
Coronavirus

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based ...

Yesterday
Pharma
Regulatory

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral ...

2 days ago
R&D
Coronavirus

Covid-19 roundup: Jun­shi, Eli Lil­ly ready to launch Covid-19 an­ti­body tri­al; Janet Wood­cock steps aside — for now ...

2 days ago
Coronavirus

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

Last month
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

4 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

6 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

7 months ago

Peer review See all

May
22

The man who led Gilead’s au­toim­mune piv­ot heads to Boston; No­var­tis gets a new chief for its AI In­no­va­tion Cen­ter

May
15

Cher­ry Thomas joins Cari­bou as SVP of clin­i­cal de­vel­op­ment; Ar­tax locks in Joseph Lobac­ki as CEO

May
8

Ex-As­traZeneca ex­ec Kris­ten Buck hops aboard Icon as CMO; Im­muno­core taps Bri­an Di­Do­na­to as CFO

May
1

High-pro­file R&D spe­cial­ist David Leb­wohl jumps to new job as CMO of a pi­o­neer­ing CRISPR play­er; Trou­bled AM­AG ...

Apr
24

Lau­ra Shawver on why she came back af­ter an $88M wind­fall; Mor­phoSys taps Am­gen vet as CCO

R&D channel feed

2 days ago

Al­ny­lam nabs speedy re­view, set­ting up 3rd pos­si­ble ap­proval in 3 years

Af­ter near­ly two decades in the haze of pre­clin­i­cal and clin­i­cal de­vel­op­ment, things seem to be com­ing in­to fo­cus for Al­ny­lam Phar­ma­ceu­ti­cals. Two years ago the com­pa­ny land­ed the ...

READ MORE

Af­ter de­cou­pling from Re­gen­eron, Sanofi says it’s time to sell the $13B stake picked up in the mar­riage

3 days ago
Deals

UP­DAT­ED: GSK adds to its trove of pos­i­tive da­ta for mul­ti­ple myelo­ma con­tender as ri­vals con­tin­ue to com­mand the ...

Yesterday
latest in R&D

UP­DAT­ED: Dupix­ent clears PhI­II tri­al in new dis­ease as block­buster looks to ex­pand past Re­gen­eron-Sanofi split

Yesterday

Be­yond cold stor­age: Tech­nol­o­gy de­signed to keep or­gans warm, helps liv­er trans­plant pa­tients in key study

2 days ago

UP­DAT­ED: Piv­otal myas­the­nia gravis da­ta from ar­genx au­gur well for FcRn in­hibitors in de­vel­op­ment

2 days ago

An­oth­er NASH de­lay for In­ter­cept frus­trates in­vestors, shares wilt

6 days ago

A new biotech from a long­time de­vel­op­er wants to bring the tar­get­ed can­cer rev­o­lu­tion to the kids left be­hind

Last week
see latest stories

Pharma channel feed

6 days ago

Ger­man Mer­ck bests US Mer­ck in UK copy­right tus­sle of Mer­ck v. Mer­ck

Be­fore Mer­ck and Mer­ck, there was on­ly Mer­ck. A sin­gle com­pa­ny was found­ed as a drug­mak­er in the pre-Bis­mar­ck­ian days of an in­dus­tri­al­iz­ing Ger­many that, in 1891, de­cid­ed to launch an ...

READ MORE

FDA ap­proves the first gener­ic for Amar­in's Vas­cepa — but is a fish oil price war im­mi­nent?

6 days ago
Regulatory

Parkin­son's pa­tients no longer need to re­ly on a nee­dle for apo­mor­phine an­ti­dote for 'of­f' episodes af­ter new FDA ...

6 days ago
Regulatory
latest in Pharma

Once val­ued at $4B, an em­bat­tled Ako­rn — nurs­ing a mar­ket cap of rough­ly $37M — files for bank­rupt­cy

Last week
Regulatory

As­traZeneca, Mer­ck push block­buster fran­chise to an­oth­er key FDA ap­proval, rel­e­gat­ing a ri­val to sec­ond-fid­dle sta­tus

Last week
Regulatory

Bris­tol My­ers Squibb spells out OS ben­e­fit of Op­di­vo/Yer­voy com­bo plus 'lim­it­ed' chemother­a­py — is it enough to change prac­tice?

3 weeks ago
R&D

As­traZeneca, Mer­ck­'s star PARP in­hibitor Lyn­parza ex­pands reach in ovar­i­an can­cer with new US ap­proval

3 weeks ago
Regulatory

No­var­tis lands cap­ma­tinib ap­proval, giv­ing them a sec­ond po­ten­tial block­buster from In­cyte

4 weeks ago
Regulatory
see latest stories

Coronavirus channel feed

2 days ago

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

When a field that de­pends on sci­en­tif­ic bench­work sud­den­ly moves on­line, what hap­pens to col­lab­o­ra­tions and the in­no­va­tion sup­ply chain? We are see­ing the an­swer to this ques­tion play ...

READ MORE

Re­searchers de­fine ex­act­ly what they saw in the first pos­i­tive remde­sivir study for Covid-19. But what's that worth ...

5 days ago
Bioregnum

Covid-19 roundup: CanSi­no beats Mod­er­na to pub­li­ca­tion of first-in-hu­man da­ta for a coro­n­avirus vac­cine

6 days ago
latest in Coronavirus

EMA ex­tends vir­tu­al-on­ly meet­ing pol­i­cy through Au­gust

Last week
Regulatory

Covid-19 roundup: BAR­DA hands As­traZeneca $1B-plus to race through PhI­II and ramp up fall de­liv­er­ies of Ox­ford’s pan­dem­ic vac­cine

Last week

Mam­moth Bio­sciences teams with GSK to put Covid-19 CRISPR tests at home, air­ports, bor­ders

Last week

Covid-19 roundup: Hit with new con­flict ac­cu­sa­tions, Janet Wood­cock steps out of the agen­cy's Covid-19 chain of com­mand

Last week
R&D

Phar­mas­set co-founder jumps in­to Covid-19 fight, with a new com­pa­ny and $215 mil­lion to get there

Last week
Venture
see latest stories